Theravance Biopharma Management
Management criteria checks 1/4
Theravance Biopharma's CEO is Rick Winningham, appointed in Jun 2014, has a tenure of 9.75 years. total yearly compensation is $6.27M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 3.42% of the company’s shares, worth $14.84M. The average tenure of the management team and the board of directors is 1.8 years and 7.3 years respectively.
Key information
Rick Winningham
Chief executive officer
US$6.3m
Total compensation
CEO salary percentage | 16.7% |
CEO tenure | 9.8yrs |
CEO ownership | 3.4% |
Management average tenure | 1.8yrs |
Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why
Apr 21Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
Mar 13Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 08CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$55m |
Sep 30 2023 | n/a | n/a | -US$61m |
Jun 30 2023 | n/a | n/a | -US$68m |
Mar 31 2023 | n/a | n/a | -US$75m |
Dec 31 2022 | US$6m | US$1m | -US$93m |
Sep 30 2022 | n/a | n/a | -US$136m |
Jun 30 2022 | n/a | n/a | -US$196m |
Mar 31 2022 | n/a | n/a | -US$226m |
Dec 31 2021 | US$4m | US$1m | -US$265m |
Sep 30 2021 | n/a | n/a | -US$266m |
Jun 30 2021 | n/a | n/a | -US$264m |
Mar 31 2021 | n/a | n/a | -US$275m |
Dec 31 2020 | US$7m | US$1m | -US$295m |
Sep 30 2020 | n/a | n/a | -US$285m |
Jun 30 2020 | n/a | n/a | -US$270m |
Mar 31 2020 | n/a | n/a | -US$247m |
Dec 31 2019 | US$6m | US$984k | -US$236m |
Sep 30 2019 | n/a | n/a | -US$221m |
Jun 30 2019 | n/a | n/a | -US$222m |
Mar 31 2019 | n/a | n/a | -US$223m |
Dec 31 2018 | US$3m | US$957k | -US$216m |
Sep 30 2018 | n/a | n/a | -US$252m |
Jun 30 2018 | n/a | n/a | -US$260m |
Mar 31 2018 | n/a | n/a | -US$285m |
Dec 31 2017 | US$2m | US$933k | -US$285m |
Compensation vs Market: Rick's total compensation ($USD6.27M) is above average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.
CEO
Rick Winningham (63 yo)
9.8yrs
Tenure
US$6,272,907
Compensation
Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 9.8yrs | US$6.27m | 3.42% $ 14.8m | |
Chief Business Officer and Senior VP of Commercial & Medical Affairs | 2.3yrs | US$942.81k | 0.65% $ 2.8m | |
Senior VP & CFO | 1.2yrs | no data | 0.50% $ 2.2m | |
VP of IT&I & Chief Information Officer | no data | no data | no data | |
Vice President of Corporate Communications & Investor Relations | no data | no data | no data | |
Senior VP | 1.8yrs | no data | 0.54% $ 2.3m | |
Senior VP & Chief Strategy Officer | 1.5yrs | no data | no data | |
SVP of Dev. | no data | no data | 0.28% $ 1.2m |
1.8yrs
Average Tenure
53.5yo
Average Age
Experienced Management: TBPH's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 10.7yrs | US$6.27m | 3.42% $ 14.8m | |
Independent Director | 9.8yrs | US$223.12k | 0.13% $ 548.6k | |
Independent Director | 10.4yrs | US$235.62k | 0.24% $ 1.0m | |
Independent Director | 3.7yrs | US$224.94k | 0.077% $ 332.3k | |
Lead Independent Director | 9.8yrs | US$218.12k | 0.15% $ 630.9k | |
Independent Director | less than a year | no data | no data | |
Independent Director | 8.4yrs | US$215.62k | 0.11% $ 477.7k | |
Independent Director | 1.1yrs | no data | 0.043% $ 188.8k | |
Independent Director | 6.1yrs | US$220.62k | 0.11% $ 484.7k | |
Independent Director | less than a year | no data | 0.024% $ 106.0k |
7.3yrs
Average Tenure
65.5yo
Average Age
Experienced Board: TBPH's board of directors are considered experienced (7.3 years average tenure).